This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert M. Post, MD; Thomas W. Uhde, MD
Biological Psychiatry Branch National Institute of Mental Health Bldg 10, Room 3N212 9000 Rockville Pike Bethesda, MD 20205

Arch Gen Psychiatry. 1984;41(2):210.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Moss and James¹ presented an interesting case of an acute but unsustained antimanic response to the combination of carbamazepine and lithium carbonate. Several points raised in their letter deserve comment and further discussion.

There are many potential reasons for the lack of a continued response to carbamazepine in combination with lithium carbonate in their case. One is dosage. The 800-mg/day dosage they employed was slightly below the average dosage in our series, with many patients being able to tolerate a higher dosage without evidence of side effects and achieving more impressive clinical responses.^2,3 The authors noted that increases in dosage were postponed because of a trend indicating slight suppression of bone marrow activity. Mild to moderate decreases in WBC count are evident in the majority of patients treated with carbamazepine; this appears to be, in part, dose related but is not thought to be related . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?